Pancreatic Cancer
Pancreatic Cancer
Advertisement
Laura LitwinPancreatic Cancer | October 31, 2024
Study participants were administered nadunolimab with a standard dose of gemcitabine and nab-paclitaxel (GN) every two weeks.
Read More
Wungki Park, MD, MSPancreatic Cancer | September 27, 2024
Dr. Wungki Park gives an overview of the POLAR study for metastatic pancreatic cancer.
Wungki Park, MD, MSPancreatic Cancer | September 27, 2024
Dr. Wungki Park of Memorial Sloan Kettering Cancer Center discusses his trial on the use of ASP3082 for solid tumors.
Jordana JampelPancreatic Cancer | September 23, 2024
The FAK inhibitor narmafotinib targets solid tumors in pancreatic cancer.
Jordana JampelPancreatic Cancer | September 19, 2024
mFOLFIRINOX plus CRT did not improve R0 resection nor OS compared with nFOLFIRINOX without CRT.
Jordana JampelPancreatic Cancer | September 17, 2024
The primary endpoint was PFS, which was a median of 3.5 months for S-1 and 3.7 months for 5-FU.
Zev Wainberg, MD, MScGastric Cancer | September 30, 2024
Dr. Wainberg reviews the data on GI malignancies and notes that it is unclear who should receive radiation before surgery.
Brandon TwyfordPancreatic Cancer | September 12, 2024
Results showed 64% of patients with HRD mPC were progression-free at 6 months with pembrolizumab and olaparib.
Jordana JampelPancreatic Cancer | September 11, 2024
A novel KRAS G12D degrader has an acceptable safety profile and positive antitumor activity, especially in pancreatic cancer.
Jordana JampelPancreatic Cancer | September 6, 2024
The use of EUS and multimodal AI across all levels of endoscopic expertise proved beneficial.
Emily MenendezPancreatic Cancer | August 9, 2024
While germline testing is recommended for patients with PDAC, many do not undergo testing.
Emily MenendezPancreatic Cancer | July 30, 2024
A new cohort study sought to determine the effect of selective surveillance on survival in patients at high risk of PDAC.
Michael Cecchini, MDPancreatic Cancer | July 26, 2024
Dr. Cecchini explains how ctDNA was used in this study as well as which methods were used for analyzing ctDNA levels.
Katy MarshallPancreatic Cancer | July 11, 2024
Research has demonstrated that DC-based immunotherapy resulted in T-cell responses against pancreatic cancer antigens.
Katy MarshallPancreatic Cancer | June 25, 2024
Patients with PDAC face difficulty achieving durable disease control when following the current standard of care.
Eric Faber, MD, PhDPancreatic Cancer | June 24, 2024
Dr. Faber highlights the implications of increased expression of PDCD1LG2, PDCD1, and HAVCR2 in USC PDAC tumors. 
Katy MarshallPancreatic Cancer | June 20, 2024
The chimeric antigen receptor-modified T-cell therapy CT041 singles out claudin18.2 in solid tumors.
Jennifer Knox, MDPancreatic Cancer | June 6, 2024
Dr. Knox details the early results of the PASS-01 trial, which looked at PDAC signature stratification for treatment.
Brandon TwyfordPancreatic Cancer | June 5, 2024
The trial compared mFOLFIRINOX vs gemcitabine/nab-paclitaxel in advanced PDAC.
Benjamin Weinberg, MD, FACPPancreatic Cancer | June 4, 2024
Dr. Weinberg explains the mechanism of action for BXCL701 and how it synergizes with pembrolizumab.
Advertisement
Advertisement
Advertisement
Latest News

November 5, 2024